Australia - angielski - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - calcium polystyrene sulfonate, quantity: 999.3 mg/g - powder - excipient ingredients: vanillin; saccharin - calcium resonium is an ion-exchange resin. it is recommended for the treatment of hyperkalaemia associated with anuria and severe oliguria.,it is also used to treat hyperkalaemia in patients requiring dialysis and in patients on regular haemodialysis or on prolonged peritoneal dialysis.

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - calcium polystyrene sulfonate 99.93% (binding capacity 1.7meq/g);  ;   - powder for oral solution - 1.7 meq/g - active: calcium polystyrene sulfonate 99.93% (binding capacity 1.7meq/g)     excipient: saccharin vanillin

Izrael - angielski - Ministry of Health

lapidot medical import and marketing ltd - calcium gluconate - solution for injection - calcium gluconate 0.94 g / 10 ml - calcium gluconate - calcium gluconate - treatment of acute symptomatic hypocalcaemia.

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

gambro renal products - calcium chloride (unii: m4i0d6vv5m) (calcium cation - unii:2m83c4r6zb, chloride ion - unii:q32zn48698), magnesium chloride (unii: 02f3473h9o) (magnesium cation - unii:t6v3lhy838, chloride ion - unii:q32zn48698), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152, chloride ion - unii:q32zn48698), sodium phosphate, dibasic (unii: gr686lba74) (sodium cation - unii:lyr4m0nh37, phosphate i - calcium chloride 0.139 g in 1 l - prismasol and phoxillum solutions are indicated in pediatric and adult patients for use as a replacement solution in continuous renal replacement therapy (crrt) to replace plasma volume removed by ultrafiltration and to correct electrolyte and acid-base imbalances.they may also be used in case of drug poisoning when crrt is used to remove dialyzable substances. none pregnancy category c animal reproduction studies have not been conducted with prismasol and phoxillum solutions. while there are no adequate and well controlled studies in pregnant women, appropriate administration of prismasol and phoxillum solutions with monitoring of fluid, electrolyte, acid-base and glucose balance, is not expected to cause fetal harm, or affect reproductive capacity. maintenance of normal acid-base balance is important for fetal well-being. the components of prismasol and phoxillum solutions are excreted in human milk. appropriate administration of prismasol and phoxillum solutions with monitoring of fluid, electrolyte, acid-

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

gambro renal products - calcium chloride (unii: m4i0d6vv5m) (calcium cation - unii:2m83c4r6zb, chloride ion - unii:q32zn48698), magnesium chloride (unii: 02f3473h9o) (magnesium cation - unii:t6v3lhy838, chloride ion - unii:q32zn48698), dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok), lactic acid (unii: 33x04xa5at) (lactic acid - unii:33x04xa5at), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698), sodium bicarbonate (unii: 8mdf5v39qo) (sodium cation - - calcium chloride 0.139 g in 1 l - there is no known contraindication to the use of prismasol solution. pregnancy category c. prismasol solution is a replacement solution of electrolytes, bicarbonate and dextrose and is pharmacologically inactive. animal reproduction studies have not been conducted with prismasol solution. while there are no adequate and well controlled studies in pregnant women, appropriate administration of prismasol solution with monitoring of fluid, electrolyte, acid-base and glucose balance, is not expected to cause fetal harm, or affect reproductive capacity. maintenance of normal acid-base balance is important for fetal well being. prismasol solution is a replacement solution of electrolytes, bicarbonate and dextrose and is pharmacologically inactive. the components of prismasol solution are excreted in human milk. appropriate administration of prismasol solution with monitoring of fluid, electrolyte, acid-base and glucose balance, is not expected to harm a nursing infant. safety and effectiveness have been established

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - glucose 40 g/l; potassium chloride 2.24 g/l; sodium chloride 1.8 g/l - solution for infusion - 30 mmol/l - active: glucose 40 g/l potassium chloride 2.24 g/l sodium chloride 1.8 g/l - for replenishing fluid losses, as an energy source and for restoration or maintenance of sodium, potassium and chloride ions in the body fluids. it may be used as a vehicle of drug delivery where intravenous delivery is appropriate and the medicine is compatible with this solution.

Malta - angielski - Medicines Authority

fresenius medical care deutschland gmbh d-61346 bad homburg, germany - calcium, glucose - solution for peritoneal dialysis - calcium 1.25 mmol/l glucose 1.5 % (w/v) - blood substitutes and perfusion solutions

Malta - angielski - Medicines Authority

fresenius medical care deutschland gmbh d-61346 bad homburg, germany - calcium, glucose - solution for peritoneal dialysis - calcium 1.25 mmol/l glucose 2.3 % (w/v) - blood substitutes and perfusion solutions

Malta - angielski - Medicines Authority

fresenius medical care deutschland gmbh d-61346 bad homburg, germany - calcium, glucose - solution for peritoneal dialysis - calcium 1.25 mmol/l glucose 4.25 % (w/v) - blood substitutes and perfusion solutions

Malta - angielski - Medicines Authority

fresenius medical care deutschland gmbh d-61346 bad homburg, germany - calcium, glucose - solution for peritoneal dialysis - calcium 1.75 mmol/l glucose 1.5 % (w/v) - blood substitutes and perfusion solutions